I think the enormity of yesterday's announcement has been...

I think the enormity of yesterday's announcement has been somewhat lost on some.
The team is having success on multiple fronts with solid tumours, on low to medium doses, with zero toxicity. As far as I know, that's unheard of. And this is a $400B untapped market that is increasing rapidly.
And now that they have released interim results, I expect the information flow to become more common as this paradigm shift phase 1 trial comes to an end in 2024. I almost expect to see the Phase 2 Recommended Dose late this year, if not early next year.
OnCARlytics news flow should be equally as often given that they are starting at a higher dose and therefore should see results faster.
Exciting times.